Evaluaciones económicas

Cost-effectiveness study of prophylaxis with emicizumab versus bypassing agents in patients with severe hemophilia A in Peru

Back to article
Cost-effectiveness analysis in adults and children with inhibitors, from Ministry of Health and Social Security Health Insurance, comparing current scheme with emicizumab prophylaxis.